University of Utah Research Foundation

Myrexis, Inc.

Navigen, Inc.

Myriad Pharmaceuticals, Inc.

Mark Shenderovich

Ashok Bajji

Mark B Anderson

Richard Trovato

Daniel Wettstein

Se-Ho Kim

Rajendra Tangallapally

Benjamin Markovitz

John A Vanecko

Hariprasad Vankayalapati

Dean Li

Kirill Ostanin

Christopher L Cioffi

Neil Moss

Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.

Arf6 inhibitors and methods of synthesis and use thereof

The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L, L, are as defined herein.

Purine-core inhibitors of HSP90 and their use in treating cancer

The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

Therapeutic compounds and their use in cancer

Growing community of inventors

Salt Lake City, UT, United States of America

Mark Shenderovich